These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221 [TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? Knauer MJ; Diamandis EP; Hulot JS; Kim RB; So DY Clin Chem; 2015 Oct; 61(10):1235-40. PubMed ID: 26272232 [No Abstract] [Full Text] [Related]
6. [CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]. Mesitskaia DF; Nikitina IuM; Kopylov FIu; Syrkin AL; Aksenova MG; Kirillov MIu; Dobrovol'skiĭ AV Klin Med (Mosk); 2015; 93(2):40-6. PubMed ID: 26117917 [TBL] [Abstract][Full Text] [Related]
7. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. Fuster V; Sweeny JM JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263 [No Abstract] [Full Text] [Related]
8. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980 [TBL] [Abstract][Full Text] [Related]
9. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel]. Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Clopidogrel: An Unresolved Issue. Pereira NL; Geske JB; Mayr M; Shah SH; Rihal CS Circ Cardiovasc Genet; 2016 Apr; 9(2):185-8. PubMed ID: 27094200 [No Abstract] [Full Text] [Related]
11. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
12. Reply to effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with Clopidogrel. Moris D; Bakoyiannis C; Karaolanis G; Georgopoulos S J Neurol Sci; 2017 Jan; 372():464. PubMed ID: 27823837 [No Abstract] [Full Text] [Related]
13. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725 [No Abstract] [Full Text] [Related]
14. [Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms]. Mesitskaia DF; Nikitina IuM; Lomakin OV; Shchekochikhin DIu; Kopylov FIu Ter Arkh; 2014; 86(9):77-82. PubMed ID: 25518510 [TBL] [Abstract][Full Text] [Related]
15. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840 [TBL] [Abstract][Full Text] [Related]
16. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Osnabrugge RL; Head SJ; Zijlstra F; ten Berg JM; Hunink MG; Kappetein AP; Janssens AC Genet Med; 2015 Jan; 17(1):3-11. PubMed ID: 24946154 [TBL] [Abstract][Full Text] [Related]
17. Clopidogrel resistance - a clear problem with an unclear solution. Bansilal S; Bhatt DL Indian Heart J; 2012; 64(4):353-5. PubMed ID: 22929816 [No Abstract] [Full Text] [Related]
18. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Simon T; Danchin N Circulation; 2017 Jan; 135(1):34-37. PubMed ID: 28028061 [No Abstract] [Full Text] [Related]
19. Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre. Petrek M; Kocourkova L; Zizkova V; Nosek Z; Taborsky M; Petrkova J Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):99-107. PubMed ID: 28083610 [TBL] [Abstract][Full Text] [Related]
20. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]